Suppression by mAbs against DQB1 peptides of in vitro proliferation of AChR-specific T cells from myasthenia gravis patients

Autoimmunity

Volumn 38, Issue 2, 2005, Pages 161-169

  Oshima, Minako ^a   Ohtani, Maki ^a   Deitiker, Philip R ^a   Smith, R Glenn ^b   Mosier, Dennis R ^a,c   Atassi, M Zouhair ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acetylcholine receptor; Antigen presenting region; MHC; Monoclonal antibodies; Myasthenia gravis

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; HLA DQB1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEPTIDE DERIVATIVE; PREDNISONE; PYRIDOSTIGMINE;

ADULT; AGED; ALLELE; ALLERGIC REACTION; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN PURIFICATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CONTROLLED STUDY; CORRELATION FUNCTION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HYBRIDOMA CELL CULTURE; IMMUNE RESPONSE; IMMUNOASSAY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PERIPHERAL LYMPHOCYTE; T LYMPHOCYTE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HLA-DQ ANTIGENS; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; T-LYMPHOCYTES;

EID: 21044440890     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.1080/08916930500050491     Document Type: Article

References (45)

1. Appel SH, Almon RR, Levy N. Acetylcholine receptor antibodies in myasthenia gravis. N Engl J Med 1975; 293:760-761.
2. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-1059.
3. Hohlfeld R, Toyka KV, Tzartoss SJ, Carson W, Conti-Tronconi B. Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor a subunit. Proc Natl Acad Sci USA 1987;84:5379-5383.
4. Richman DP, Agius MA. Treatment principles in the management of autoimmune myasthenia gravis. Ann N Y Acad Sci 2003;998:457-472.
5. Donaldson DH, Ansher M, Horan S, Rutherford RB, Ringel SP. The relationship of age to outcome in myasthenia gravis. Neurology 1990;40:786-790.
6. Bell J, Rassenti L, Smoot S, Smith K, Newby C, Hohlfeld R, Toyka K, McDevitt H, Steinman L. HLA-DQ beta-chain polymorphism linked to myasthenia gravis. Lancet 1986;i:1058-1060.
7. Christadoss P, Lindstrom JM, Melvold RW, Talal N. Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis. Immunogenetics 1985;21: 33-38.
8. b on binding with and antigen presentation of Torpedo acetylcholine receptor α chain peptide 146-162. J Immunol 1995;154:5245-5254.
9. Infante AJ, Thompson PA, Krolick KA, Wall KA. Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes. J Immunol 1991;146: 2977-2982.
10. + cells sensitized to nicotinic acetylcholine receptor. J Immunol 1991;147:1484-1491.
11. Shenoy M, Oshima M, Atassi MZ, Christadoss P. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region α146-162 of acetylcholine receptor. Clin Immunol Immunopath 1993;66: 230-238.
12. Nakayashiki N, Oshima M, Deitiker PR, Ashizawa T, Atassi MZ. Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T-cell epitope. J Neuroimmunol 2000;105:131-144.
13. Oshima M, Deitiker P, Ashizawa T, Atassi MZ. Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG. Autoimmunity 2002;35:183-190.
14. Garchon HJ. Genetics of autoimmune myasthenia gravis, a model for antibody-mediated autoimmunity in man. J Autoimmun 2003;21:105-110.
15. Matsuki K, Juji T, Tokunaga K, Takamizawa M, Maeda H, Soda M, Nomura Y, Segawa M. HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest 1990;86: 392-399.
16. Hjelmstrom P, Peacock CS, Giscombe R, Pirskanen R, Lefvert AK, Blackwell JM, Sanjeevi CB. Myasthenia gravis with thymic hyperplasia is associated with polymorphisms in the tumor necrosis factor region. Ann N Y Acad Sci 1998;841:368-370.
17. Horiki T, Inoko H, Moriuchi J, Ichikawa Y, Arimori S. Combinations of HLA-DPB1 and HLA-DQB1 alleles determine susceptibility to early-onset myasthenia gravis in Japan. Autoimmunity 1994;19:49-54.
18. Vieira ML, Caillat-Zucman S, Gajdos P, Cohen-Kaminsky S, Casteur A, Bach J-F. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J Neuroimmunol 1993;47:115-122.
19. Baggi F, Antozzi C, Andreetta F, Confaloniri P, Ciusani E, Begovich AB, Erlich HA, Cornelio A, Mantegazza R. Identification of a novel HLA class II association with DQB1*0502 in an Italian myasthenic population. Ann N Y Acad Sci 1998;841:355-359.
20. Hjelmstrom P, Giscombe R, Lefvert AK, Pirskanen R, Kockum I, Landin-Olsson M, Sanjeevi CB. Polymorphic amino acid domains of the HLA-DQ molecules are associated with disease heterogeneity in myasthenia gravis. J Neuroimmunol 1996;65:125-131.
21. Suzuki S, Kuwana M, Yasuoka H, Tanaka K, Fukuuchi Y, Kawakami Y. Heterogeneous immunogenetic background in Japanese adults with myasthenia gravis. J Neurol Sci 2001;189:59-64.
22. Yasunaga S, Kimura A, Hamaguchi K, Ronningen KS, Sasazuki T. Different contribution of HLA-DR and -DQ genes in susceptibility and resistance to insulin-dependent diabetes mellitus (IDDM). Tissue Antigens 1996;47:37-48.
23. Atassi MZ, Kazim AL, Sakata S. High yield coupling of peptides to protein carriers. Biochim Biophys Acta 1981;670:300-302.
24. Mulac-Jericevic B, Manshouri T, Yokoi T, Atassi MZ. The regions of α-neurotoxin binding on the extracellular part of the α-subunit of human acetylcholine receptor. J Prot Chem 1988; 7:173-177.
25. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, et al. Myasthenia gravis: Recommendations for clinical research standards. Neurology 2000;55:16-23.
26. Oshima M, Ashizawa T, Pollack MS, Atassi MZ. Autoimmune T cell recognition of human acetylcholine receptor: The sites of T cell recognition in myasthenia gravis on the extra-cellular part of the α subunit. Eur J Immunol 1990; 20:2563-2569.
27. Giles RC, Nunez G, Hurley CK, Nunez-Roldan A, Winchester R, Stastny P, Capra JD. Structural analysis of a human I-A homologue using a monoclonal antibody that recognizes an MB3-like specificity. J Exp Med 1983; 157:1461-1470.
28. Wall M, Southwood S, Sidney J, Oseroff C, del Guericio MF, Lamont AG, Colon SM, Arrhenius T, Gaeta FCA, Sette A. High affinity for class II molecules as a necessary but not sufficient characteristic of encephalitogenic determinants. Int Immunol 1992;4:773-777.
29. Twining SS, Atassi MZ. Use of immunoadsorbents for the study of antibody binding to sperm whale myoglobin and its synthetic antigenic sites. J Immunol Methods 1979;30: 139-151.
30. Hohlfeld R, Kalies I, Kohleisen B, Heininger K, Conti-Tronconi B, Toyka KV. Myasthenia gravis: Stimulation of antireceptor autoantibodies by autoreactive T cell lines. Neurology 1986;36:618-621.
31. Ofosu-Appiah W, Mokhtarian F, Shirazian D, Grob D. Production of anti-acetylcholine receptor-α antibody in vitro by peripheral blood lymphocytes of patients with myasthenia gravis: Role of immunoregulatory T cells and monocytes. J Lab Clin Med 1994;124:231-241.
32. Rosenberg JS, Oshima M, Atassi MZ. B-cell activation in vitro by helper T cells specific to region α146-162 of Torpedo californica nicotinic acetylcholine receptor. J Immunol 1996;157:3192-3199.
33. Nagvekar N, Corlett L, Jacobson LW, Matsuo H, Chalkley R, Driscoll PC, Deshpande S, Spack EG, Willcox N. Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: Overlapping natural and artificial determinants in the human acetylcholine receptor. J Immunol 1999;162: 4079-4087.
34. Zhang Y, Schluep M, Frutiger S, Hughes GJ, Jeannet M, Steck A, Barkas T. Immunological heterogeneity of autoreactive T lymphocytes against the nicotinic acetylcholine receptor in myasthenic patients. Eur J Immunol 1990; 20:2577-2583.
35. Kanai T, Nomura Y, Segawa M, Takagi K, Senju S, Matsushita S, Nishimura Y. Immuno-suppressive peptides for a human T cell clone autoreactive to a unique acetylcholine receptor alpha subunit peptide presented by the disease-susceptible HLA-DQ6 in infant-onset myasthenia gravis. Hum Immunol 1997;56:28-38.
36. Todd JA, Acha-Orbea H, Bell JL, Chao N, Fronek Z, Jacob CO, McDermott M, Sinh AA, Timmerman L, Steinman L, McDevitt HO. A molecular basis for MHC class II-associated autoimmunity. Science 1988;240:1003-1009.
37. Bugawan TL, Angelini G, Larrick J, Auricchio S, Ferrarar GB, Erlich HA. A combination of a particular HLA-DP β allele and an HLA-DQ heterodimer confers susceptibility to coeliac disease. Nature 1989;339:470-473.
38. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban G, Strominger JL, Wiley DC. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994;368:215-221.
39. Topham DJ, Nag B, Arimilli S, Sriram S. A synthetic peptide from the third hypervariable region of major histocompatibility complex class II β chain as a vaccine for treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1994;91:8005-8009.
40. Atassi MZ, Young CR. Discovery and implications of the immunogenicity of free small synthetic peptides. Powerful tools for manipulating the immune system and for production of antibodies and T-cells of preselected submolecular specificities. Crit Rev Immunol 1985;5:387-410.
41. Dressman GR, Sanchez Y, Ionescu-Matiu I, Sparrow JT, Six HR, Peterson DL, Hollinger FB, Melnick JL. Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HbsAg peptides. Nature 1982; 295:158-160.
42. Oshima M, Deitiker PR, Mosier DR, Smith RG, Atassi MZ. Responses in vitro of peripheral blood lymphocytes from myasthenia gravis patients to stimulation with human AChR α-chain peptides: Analysis in relation to age, thymic abnormality and ethnicity. Hum Immunol 2005;66:32-42.
43. Buckner J, Kwok WW, Nepom B, Nepom GT. Modulation of HLA-DQ binding properties by differences in class II dimer stability and pH-dependent peptide interactions. J Immunol 1996;157:4940-4945.
44. Kaufman JF, Strominger JL. HLA-DR light chain has a polymorphic N-terminal region and a conserved immunoglobulin-like C-terminal region. Nature 1982;297:694-697.
45. Adorini L, Guery J-C, Rodriguez-Tarduchy G, Trembleau S. Selective immunosuppression. Immunol Today 1993; 14:285-289.